The Estrogen Dial — How rs727479 Controls Your Aromatase Output
Estrogen doesn't come only from the ovaries. After menopause — and throughout life in
men and premenopausal women — a substantial fraction of circulating estradiol is made
locally in adipose tissue, bone, brain, and liver through the action of
aromatase | the enzyme encoded by CYP19A1 that converts androgens such as testosterone
and androstenedione into estrogens. The amount
of aromatase produced in peripheral tissues is controlled partly by which alleles you
carry at regulatory sites within CYP19A1. rs727479, a variant in intron 4 of the gene,
has emerged through multiple independent genome-wide association studies as the single
best common genetic predictor of circulating estradiol levels — particularly in
postmenopausal women, when peripheral aromatase becomes the dominant source of estrogen.
The Mechanism
rs727479 is located at chr15:51242349 (GRCh38), within an intron of CYP19A1 on the
minus strand of chromosome 15. It does not alter the aromatase protein sequence; instead,
it influences gene expression. Glubb et al. demonstrated that the variant
alters binding motifs for four transcription factors and lies within a putative
regulatory element | Glubb DM et al. The Association of CYP19A1 Variation with
Circulating Estradiol and Aromatase Inhibitor Outcome. Front Pharmacol 2017,
providing a direct mechanistic explanation for why C-allele carriers produce less
aromatase mRNA in peripheral tissues. Because CYP19A1 is regulated by tissue-specific
promoters, the effect is most pronounced in tissues that rely on intronic regulatory
elements — including adipose and bone — where aromatase expression in postmenopausal
women accounts for the majority of total-body estrogen synthesis.
The C allele at this position is the minor allele globally (~29%), with the common A
allele carried by ~71% of people. In genome files, alleles are reported on the plus
strand: A is the common allele associated with normal aromatase expression, and C is
the minor allele associated with lower expression and lower estradiol.
The Evidence
Circulating estradiol. Prescott et al. conducted a genome-wide association study
in ~1,600 postmenopausal women not using hormone therapy | Prescott J et al.
Genome-wide association study of circulating estradiol, testosterone, and sex
hormone-binding globulin in postmenopausal women. PLoS One 2012.
rs727479 was the top signal at the CYP19A1 locus for circulating estradiol
(β = −0.107, p = 5.11×10⁻⁷), with 34 additional correlated SNPs in the region
reaching p < 10⁻⁵. Glubb et al. subsequently synthesized data across four large
studies totalling more than 10,000 women | Glubb DM et al. Front Pharmacol 2017
and identified rs727479 as the variant that best captures the estradiol signal across
the locus, with effect sizes of 5–10.7% lower estradiol per C allele (p = 1.3×10⁻¹⁰
in the largest dataset). All other associated CYP19A1 variants were in linkage
disequilibrium with rs727479 (r² = 0.10–0.51), confirming a single genetic signal.
Bone mineral density. Estradiol is a key suppressor of osteoclast-driven bone
resorption. Eriksson et al. used Mendelian randomization in 11,097 men to establish a
causal link between CYP19A1-driven circulating estradiol and lumbar spine bone mineral
density | Ruth KS et al. Genetic Determinants of Circulating Estrogen Levels and
Evidence of a Causal Effect of Estradiol on Bone Density in Men.
J Clin Endocrinol Metab 2018: each
1 pg/mL genetically higher estradiol was associated with a 0.048 SD increase in
lumbar spine BMD. This finding is consistent with the known biology of estrogen
deficiency and osteoporosis, and extends it to genetic variation in estrogen
biosynthesis.
Endometrial cancer. Thompson et al. fine-mapped the CYP19A1 locus and applied
Mendelian randomization to establish that the estradiol-raising allele causally
increases endometrial cancer risk | Thompson DJ et al. CYP19A1 fine-mapping and
Mendelian randomization: estradiol is causal for endometrial cancer.
Endocr Relat Cancer 2016. rs727479 was
among the lead variants at the locus; the C allele (lower estradiol) corresponds to
lower endometrial cancer risk.
Late-life depression. Ancelin et al. followed 1,007 adults aged 65 or older
and found that CYP19A1 estradiol-modulating variants were associated with depression
risk in a sex-specific pattern | Ancelin ML et al. Aromatase (CYP19A1) gene variants,
sex steroid levels, and late-life depression. Depress Anxiety 2020.
In postmenopausal women without prior depression, lower-estradiol genotypes increased
incident depression risk; in women with prior depression, some variants were protective.
This reflects the known role of estrogen in modulating serotonergic and noradrenergic
neurotransmitter systems.
Aromatase inhibitor response. Because rs727479 predicts baseline aromatase output,
individuals with higher baseline aromatase expression (AA genotype) require more
complete suppression to achieve the same absolute estradiol reduction during aromatase
inhibitor therapy. The clinical significance for treatment outcomes remains an active
area of investigation.
Practical Actions
Carriers of the CC genotype produce meaningfully less estrogen through peripheral
aromatase. In postmenopausal women, this translates to clinically lower serum estradiol,
which has downstream effects on bone density, cardiovascular risk, mood, and
endometrial cancer risk (reduced in CC carriers). Monitoring bone density and being
aware of estrogen-deficiency-related symptoms is specifically warranted.
For women undergoing aromatase inhibitor therapy (letrozole, anastrozole), CC carriers
start with already-low peripheral estrogen; their symptoms of estrogen deficiency during
AI therapy may be more pronounced. Conversely, AA homozygotes (higher aromatase output)
may require confirmation that AI therapy is achieving adequate estradiol suppression.
For men with prostate cancer, the C-allele direction (lower aromatase-mediated estrogen
synthesis) translates to higher androgen-to-estrogen ratios, which may influence
hormone-sensitive tumor biology and response to androgen deprivation therapy.
Interactions
rs727479 sits within a CYP19A1 haplotype block alongside rs4775936 (I.6 promoter
variant associated with BMD and AI response), rs2414096 (intron 4 variant associated
with PCOS and androgen levels), and rs2414095 (intron 3 variant). These variants are
in linkage disequilibrium (r² = 0.10–0.51) and their combined haplotype consistently
shows stronger associations than any single SNP alone. In downstream signaling, the
estrogen produced by aromatase must bind to estrogen receptors encoded by ESR1 (see
related variant rs9340799) — so the combination of altered aromatase output (CYP19A1)
and altered receptor sensitivity (ESR1) can amplify or dampen the functional consequences.
Alla genotyper
Common genotype — normal peripheral aromatase expression and circulating estradiol
You carry two copies of the common A allele at rs727479. This genotype is associated with typical aromatase expression in peripheral tissues (adipose, bone, brain) and normal circulating estradiol levels. About 49% of people globally share this genotype, making it the most common. The A allele is the major allele at this locus in every population studied. Your aromatase output in peripheral tissues follows the baseline pattern established in large-scale GWAS studies of circulating estradiol in postmenopausal women.
One copy of the C allele — modestly lower peripheral aromatase expression and estradiol
You carry one C allele and one A allele at rs727479. This heterozygous genotype is found in approximately 42% of people globally and is the most common genotype at this locus. The C allele is the minor allele associated with lower aromatase expression in peripheral tissues; carrying one copy produces an intermediate reduction in circulating estradiol. The Glubb 2017 synthesis of four large studies estimated a 5–7% lower estradiol per C allele in postmenopausal women, so heterozygotes have modestly but measurably lower peripheral estrogen synthesis. This is most clinically relevant after menopause, when peripheral aromatase becomes the dominant estrogen source.
Two copies of the C allele — lowest common level of peripheral aromatase expression and circulating estradiol
You carry two copies of the C allele, the minor allele at rs727479. This genotype is present in approximately 9% of people globally. Across four large genetic studies totalling more than 10,000 postmenopausal women, the CC genotype was associated with the lowest circulating estradiol from peripheral aromatase, with effect sizes of roughly 10–21% lower estradiol compared to AA homozygotes (up to p = 1.3×10⁻¹⁰). rs727479 has been identified as the single best common genetic predictor of circulating estradiol levels at the CYP19A1 locus. In postmenopausal women, when the ovaries no longer produce estrogen and peripheral aromatase is the primary source, this genotype translates to chronically low systemic estrogen levels.